Search

Your search keyword '"Stillebroer, Alexander B."' showing total 35 results
Start Over Author "Stillebroer, Alexander B."
35 results on '"Stillebroer, Alexander B."'

5. Addressing bladder and bowel challenges in dutch multiple sclerosis patients: Symptom prevalence and patient referral pathways.

Author

Faber, Willemijn and Stillebroer, Alexander B.

Subjects
*MEDICAL personnel, *SPINAL cord injuries, *AUTUMN, *MULTIPLE sclerosis, *PHYSICIANS
Abstract

Objectives: Nerve damage and/or spinal cord injury in individuals with multiple sclerosis (MS) may result in the development of bladder and bowel problems. We wanted to gain insight into two issues: the prevalence of bladder and bowel problems among individuals with MS and the referral pathways for these problems to various physicians treating patients with MS. Methods: In the autumn of 2021, we undertook a nationwide cross-sectional study. We used a comprehensive questionnaire comprising 63 questions covering aspects such as MS diagnosis, disease progression, bladder and bowel issues, and consultations with healthcare professionals. Individuals with MS were invited to participate through social media or by direct mail. Results: The study included 1,082 validated respondents (81.5% female) with an average age of 53.3 years at participation, and an average age of 38.3 years at MS-diagnosis. Among the respondents, 91% experienced bladder problems while 73% indicated they had bowel problems. Within these respective groups, 42% and 47% were not aware of the connection between these issues and MS. Bladder and bowel related complaints disrupted daily life for 45% and 28% of the respondents, respectively. The patients consulted various healthcare providers for their complaints. Most respondents expressed dissatisfaction with the time it took to resolve their problems and 9% of those with bladder complaints and 60% of those with bowel complaints had not yet found a satisfactory solution. Conclusions: In the Netherlands, bladder and bowel symptoms in individuals with MS are highly prevalent and have a considerable impact on quality of life. Lack of awareness of these symptoms frequently leads to inadequate recognition, both by the patient and healthcare professional. Patients often consult various healthcare professionals for these complaints, which can potentially result in suboptimal treatment due to a lack of specialized expertise. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Two-Staged Sacral Neuromodulation for the Treatment of Nonobstructive Urinary Retention:A Multicenter Study Assessing Predictors of Success

Author

Coolen, Rosa L., Groen, Jan, Stillebroer, Alexander B., Scheepe, Jeroen R., Witte, Lambertus P.W., Blok, Bertil F.M., Coolen, Rosa L., Groen, Jan, Stillebroer, Alexander B., Scheepe, Jeroen R., Witte, Lambertus P.W., and Blok, Bertil F.M.

Abstract

Objectives: The aims of this study were to 1) determine the success rate of the tined lead test phase in patients with nonobstructive urinary retention (NOUR), 2) determine predictive factors of a successful test phase in patients with NOUR, and 3) determine long-term treatment efficacy and satisfaction in patients with NOUR. Materials and Methods: The first part was a multicenter retrospective study at two centers in The Netherlands. Patients with NOUR received a four-week tined lead test phase. Success was defined as a ≥50% reduction of clean intermittent catheterization frequency or postvoid residual. We analyzed possible predictors of success with multivariable logistic regression. Second, all patients received a questionnaire to assess efficacy, perceived health (Patient Global Impression of Improvement), and treatment satisfaction. Results: This study included 215 consecutive patients (82 men and 133 women) who underwent a tined lead test phase for the treatment of NOUR. The success rate in women was significantly higher than in men, respectively 62% (83/133) and 22% (18/82, p < 0.001). In women, age per ten years (odds ratio [OR] 0.74, 95% CI: 0.59–0.93) and a history of psychiatric illness (OR 3.92, 95% CI: 1.51–10.2), including posttraumatic stress disorder (PTSD), significantly predicted first stage sacral neuromodulation (SNM) success. In men, age per ten years (OR 0.43, 95% CI: 0.25–0.72) and previous transurethral resection of the prostate and/or bladder neck incision (OR 7.71, 95% CI: 1.43–41.5) were significant predictors of success. Conversely, inability to void during a urodynamic study (for women, OR 0.79, 95% CI: 0.35–1.78; for men, OR 3.06, 95% CI: 0.83–11.3) was not predictive of success. Of the patients with a successful first stage, 75% (76/101) responded to the questionnaire at a median follow-up of three years. Of these patients, 87% (66/76) continued to use their SNM system, and 92% (70/76) would recommend SNM to other patients. Concl

Published
2023

8. DEVELOPMENT OF NOVEL PCA3 CUT-OFFS FOR INITIAL AND REPEAT BIOPSY USING DIFFERENT STATISTICAL APPROACHES WITHIN A US- EUROPEAN MULTI INSTITUTIONAL COHORT: 1216

Author

Chun, Felix K.H., Haese, Alexander, de la Taille, Alexandre, van Poppel, Henk, Marberger, Michael, Mulders, Peter F.A., Abbou, Clemens C., Stillebroer, Alexander B., Van Gils, Martijn P.M.Q., Schalken, Jack A., Stenzl, Arnulf, Fradet, Yves, Marks, Leonard S., Ellis, W., Partin, Alan W., Walz, Jochen, and Auprich, Marco

Published
2012

9. BIOPSY-SPECIFIC PCA3- BASED PROSTATE BIOPSY NOMOGRAMS ARE HIGHLY ACCURATE: 1210

Author

Chun, Felix K.-H., Hansen, Jens, de la Taille, Alexandre, van Poppel, Hendrik, Marberger, Michael, Stenzl, Arnulf, Mulders, Peter F.A., Huland, Hartwig, Abbou, Clement-Claude, Stillebroer, Alexander B., van Gils, Martin P.M.Q., Schalken, Jack A., Fradet, Yves, Marks, Leonard S., Ellis, William, Partin, Alan W., Pummer, Karl, Haese, Alexander, and Auprich, Marco

Published
2012

10. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

Author

Ploussard, Guillaume, Haese, Alexander, Van Poppel, Hendrik, Marberger, Michael, Stenzl, Arnulf, Mulders, Peter F.A., Huland, Hartwig, Bastien, Laurence, Abbou, Clèment-Claude, Remzi, Mesut, Tinzl, Martina, Feyerabend, Susan, Stillebroer, Alexander B., Van Gils, Martijn P.M.Q., Schalken, Jack A., and De La Taille, Alexandre

Published
2010
Full Text
View/download PDF

11. Geen kanker, maar een sjanker

Author

Prins, Fieke M., Lock, M. T.W.T., Stillebroer, Alexander B., Dik, Pieter, and van der Meer, Gretha T.

Subjects
Medicine(all), Journal Article, English Abstract
Abstract

BACKGROUND: Syphilis (lues) is a sexually transmitted infection caused by the spirochete Treponema pallidum. In adolescents, the diagnosis of primary syphilis can be made promptly by taking a sexual medical history and inspecting the glans penis. CASE DESCRIPTION: A 17-year-old male was referred to the paediatric oncology centre for additional diagnostics due to inguinal lymphadenopathy, with a strong suspicion of a malignant lymphoma. None of the physicians took a sexual medical history or investigated the glans penis, as a result of which essential information was lacking. The combination of inguinal lymphadenopathy and the ultrasound findings for the inguinal region made the physicians only consider a malignancy. However, it actually concerned a reactive lymphadenopathy associated with primary syphilis. CONCLUSION: This case demonstrates that a full medical history and thorough physical examination can prevent the need for costly and invasive diagnostics.

Published
2019

12. Geen kanker, maar een sjanker

Author

UMC Utrecht, Cancer, Urologie Onderzoek, Other research (not in main researchprogram), Urologie Medisch Kinderen, Prins, Fieke M., Lock, M. T.W.T., Stillebroer, Alexander B., Dik, Pieter, van der Meer, Gretha T., UMC Utrecht, Cancer, Urologie Onderzoek, Other research (not in main researchprogram), Urologie Medisch Kinderen, Prins, Fieke M., Lock, M. T.W.T., Stillebroer, Alexander B., Dik, Pieter, and van der Meer, Gretha T.

Published
2019

13. Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Author

Muselaers, Constantijn H.J., primary, Boers-Sonderen, Marye J., additional, van Oostenbrugge, Tim J., additional, Boerman, Otto C., additional, Desar, Ingrid M.E., additional, Stillebroer, Alexander B., additional, Mulder, Sasja F., additional, van Herpen, Carla M.L., additional, Langenhuijsen, Johan F., additional, Oosterwijk, Egbert, additional, Oyen, Wim J.G., additional, and Mulders, Peter F.A., additional

Published
2016
Full Text
View/download PDF

14. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Author

Muselaers, Constantijn H J, Boers-Sonderen, Marye J, van Oostenbrugge, Tim J, Boerman, Otto C, Desar, Ingrid M E, Stillebroer, Alexander B, Mulder, Sasja F, van Herpen, Carla M L, Langenhuijsen, Johan F, Oosterwijk, Egbert, Oyen, Wim J G, Mulders, Peter F A, Muselaers, Constantijn H J, Boers-Sonderen, Marye J, van Oostenbrugge, Tim J, Boerman, Otto C, Desar, Ingrid M E, Stillebroer, Alexander B, Mulder, Sasja F, van Herpen, Carla M L, Langenhuijsen, Johan F, Oosterwijk, Egbert, Oyen, Wim J G, and Mulders, Peter F A

Published
2015

16. Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma

Author

Muselaers, Constantijn H.J., primary, Stillebroer, Alexander B., additional, Desar, Ingrid M.E., additional, Boers-Sonderen, Marye J., additional, van Herpen, Carla M.L., additional, de Weijert, Mirjam C.A., additional, Langenhuijsen, Johan F., additional, Oosterwijk, Egbert, additional, Leenders, William P.J., additional, Boerman, Otto C., additional, Mulders, Peter F.A., additional, and Oyen, Wim J.G., additional

Published
2014
Full Text
View/download PDF

17. Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Author

Stillebroer, Alexander B., primary, Boerman, Otto C., additional, Desar, Ingrid M.E., additional, Boers-Sonderen, Marije J., additional, van Herpen, Carla M.L., additional, Langenhuijsen, Johannes F., additional, Smith-Jones, Peter M., additional, Oosterwijk, Egbert, additional, Oyen, Wim J.G., additional, and Mulders, Peter F.A., additional

Published
2013
Full Text
View/download PDF

19. 1216 DEVELOPMENT OF NOVEL PCA3 CUT-OFFS FOR INITIAL AND REPEAT BIOPSY USING DIFFERENT STATISTICAL APPROACHES WITHIN A US- EUROPEAN MULTI INSTITUTIONAL COHORT

Author

Chun, Felix K.H., primary, Haese, Alexander, additional, de la Taille, Alexandre, additional, van Poppel, Henk, additional, Marberger, Michael, additional, Mulders, Peter F.A., additional, Abbou, Clemens C., additional, Stillebroer, Alexander B., additional, Van Gils, Martijn P.M.Q., additional, Schalken, Jack A., additional, Stenzl, Arnulf, additional, Fradet, Yves, additional, Marks, Leonard S., additional, Ellis, W., additional, Partin, Alan W., additional, Walz, Jochen, additional, and Auprich, Marco, additional

Published
2012
Full Text
View/download PDF

20. 1210 BIOPSY-SPECIFIC PCA3- BASED PROSTATE BIOPSY NOMOGRAMS ARE HIGHLY ACCURATE

Author

Chun, Felix K.-H., primary, Hansen, Jens, additional, de la Taille, Alexandre, additional, van Poppel, Hendrik, additional, Marberger, Michael, additional, Stenzl, Arnulf, additional, Mulders, Peter F.A., additional, Huland, Hartwig, additional, Abbou, Clement-Claude, additional, Stillebroer, Alexander B., additional, van Gils, Martin P.M.Q., additional, Schalken, Jack A., additional, Fradet, Yves, additional, Marks, Leonard S., additional, Ellis, William, additional, Partin, Alan W., additional, Pummer, Karl, additional, Haese, Alexander, additional, and Auprich, Marco, additional

Published
2012
Full Text
View/download PDF

21. Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging

Author

Stillebroer, Alexander B., primary, Zegers, Catharina M.L., additional, Boerman, Otto C., additional, Oosterwijk, Egbert, additional, Mulders, Peter F.A., additional, O'Donoghue, Joseph A., additional, Visser, Eric P., additional, and Oyen, Wim J.G., additional

Published
2011
Full Text
View/download PDF

22. 987 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON SCORE ≥ 7) AT BIOPSY

Author

Auprich, Marco, primary, Haese, Alexander, additional, van Poppel, Hendrik, additional, Marberger, Michael, additional, Stenzl, Arnulf, additional, Mulders, Peter F.A., additional, Huland, Hartwig, additional, Abbou, Clement-Claude, additional, Stillebroer, Alexander B., additional, van Gils, Martin P.M.Q., additional, Schalken, Jack A., additional, Fradet, Yves, additional, Marks, Leonard S., additional, de la Taille, Alexandre, additional, Ellis, William, additional, Partin, Alan W., additional, and Chun, Felix K.-H., additional

Published
2011
Full Text
View/download PDF

23. 2320 INITIAL AND REPEAT PROSTATE BIOPSY: COMPARATIVE PERFORMANCE ANALYSIS OF PSA, %FPSA, PROSTATE VOLUME AND URINARY PCA3 INCLUDING DEVELOPMENT OF NOVEL PCA3 CUT-OFF THRESHOLDS

Author

Auprich, Marco, primary, van Poppel, Hendrik, additional, Marberger, Michael, additional, Stenzl, Arnulf, additional, Mulders, Peter F.A., additional, Huland, Hartwig, additional, Abbou, Clement-Claude, additional, Stillebroer, Alexander B., additional, van Gils, Martin P.M.Q., additional, Schalken, Jack A., additional, Fradet, Yves, additional, Marks, Leonard S., additional, de la Taille, Alexandre, additional, Ellis, William, additional, Partin, Alan W., additional, and Haese, Alexander, additional

Published
2011
Full Text
View/download PDF

24. 111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib

Author

Desar, Ingrid M.E., primary, Stillebroer, Alexander B., additional, Oosterwijk, Egbert, additional, Leenders, William P.J., additional, van Herpen, Carla M.L., additional, van der Graaf, Winette T.A., additional, Boerman, Otto C., additional, Mulders, Peter F.A., additional, and Oyen, Wim J.G., additional

Published
2010
Full Text
View/download PDF

26. Reply to Juan Morote’s Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659–68

Author

Chun, Felix K., primary, de la Taille, Alexandre, additional, van Poppel, Hendrik, additional, Marberger, Michael, additional, Stenzl, Arnulf, additional, Mulders, Peter F.A., additional, Huland, Hartwig, additional, Abbou, Clement-Claude, additional, Stillebroer, Alexander B., additional, van Gils, Martijn P.M.Q., additional, Schalken, Jack A., additional, Fradet, Yves, additional, Marks, Leonard S., additional, Ellis, William, additional, Partin, Alan W., additional, and Haese, Alexander, additional

Published
2010
Full Text
View/download PDF

27. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram

Author

Chun, Felix K., primary, de la Taille, Alexandre, additional, van Poppel, Hendrik, additional, Marberger, Michael, additional, Stenzl, Arnulf, additional, Mulders, Peter F.A., additional, Huland, Hartwig, additional, Abbou, Clement-Claude, additional, Stillebroer, Alexander B., additional, van Gils, Martijn P.M.Q., additional, Schalken, Jack A., additional, Fradet, Yves, additional, Marks, Leonard S., additional, Ellis, William, additional, Partin, Alan W., additional, and Haese, Alexander, additional

Published
2009
Full Text
View/download PDF

33. Two-Staged Sacral Neuromodulation for the Treatment of Nonobstructive Urinary Retention: A Multicenter Study Assessing Predictors of Success

Author

Coolen, Rosa L., Groen, Jan, Stillebroer, Alexander B., Scheepe, Jeroen R., Witte, Lambertus P.W., and Blok, Bertil F.M.

Abstract

The aims of this study were to 1) determine the success rate of the tined lead test phase in patients with nonobstructive urinary retention (NOUR), 2) determine predictive factors of a successful test phase in patients with NOUR, and 3) determine long-term treatment efficacy and satisfaction in patients with NOUR.

Published
2022
Full Text
View/download PDF

34. [A chancre instead of cancer].

Author

Prins FM, Lock MTWT, Stillebroer AB, Dik P, and van der Meer GT

Subjects
Adolescent, Chancre microbiology, Humans, Inguinal Canal, Lymphadenopathy diagnostic imaging, Male, Medical History Taking, Penis, Physical Examination, Sexual Behavior, Ultrasonography, Diagnostic Errors, Lymphadenopathy microbiology, Neoplasms diagnosis, Syphilis complications, Syphilis diagnosis
Abstract

Background: Syphilis (lues) is a sexually transmitted infection caused by the spirochete Treponema pallidum. In adolescents, the diagnosis of primary syphilis can be made promptly by taking a sexual medical history and inspecting the glans penis., Case Description: A 17-year-old male was referred to the paediatric oncology centre for additional diagnostics due to inguinal lymphadenopathy, with a strong suspicion of a malignant lymphoma. None of the physicians took a sexual medical history or investigated the glans penis, as a result of which essential information was lacking. The combination of inguinal lymphadenopathy and the ultrasound findings for the inguinal region made the physicians only consider a malignancy. However, it actually concerned a reactive lymphadenopathy associated with primary syphilis., Conclusion: This case demonstrates that a full medical history and thorough physical examination can prevent the need for costly and invasive diagnostics.

Published
2019

35. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.

Author

Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O'Donoghue JA, Visser EP, and Oyen WJ

Subjects
Adult, Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal pharmacokinetics, Beta Particles adverse effects, Beta Particles therapeutic use, Carcinoma, Renal Cell blood, Carcinoma, Renal Cell diagnostic imaging, Carcinoma, Renal Cell metabolism, Female, Humans, Indium Radioisotopes, Kidney Neoplasms blood, Kidney Neoplasms diagnostic imaging, Kidney Neoplasms metabolism, Lutetium therapeutic use, Male, Middle Aged, Radiometry, Radionuclide Imaging, Radiotherapy Dosage, Antibodies, Monoclonal therapeutic use, Bone Marrow radiation effects, Carcinoma, Renal Cell radiotherapy, Kidney Neoplasms radiotherapy, Radiation Dosage, Radioimmunotherapy methods
Abstract

Unlabelled: This study aimed to estimate the radiation absorbed doses to normal tissues and tumor lesions during radioimmunotherapy with (177)Lu-cG250. Serial planar scintigrams after injection of (111)In-cG250 or (177)Lu-cG250 in patients with metastasized renal cell carcinoma were analyzed quantitatively. The estimated radiation doses were correlated with observed hematologic toxicity. In addition, the accuracy of the predicted therapeutic absorbed doses, based on diagnostic (111)In-cG250 data, were determined., Methods: Twenty patients received a diagnostic tracer activity of (111)In-cG250 (185 MBq), followed by radioimmunotherapy with (177)Lu-cG250. The administered activity of (177)Lu-cG250 was escalated by entering 3 patients at each activity level starting at 1,110 MBq/m(2), with increments of 370 MBq/m(2). After each diagnostic and therapeutic administration, whole-body scintigraphic images and pharmacokinetic data were acquired. Hematologic toxicity was graded using the Common Toxicity Criteria, version 3.0. Diagnostic (111)In-cG250 data were used to simulate (177)Lu and (90)Y data by correcting for the difference in physical decay. Absorbed doses were calculated for the whole body, red marrow, organs, and tumor metastases for the therapeutic (177)Lu-cG250, simulated (177)Lu-cG250, and simulated (90)Y-cG250 data., Results: Observed hematologic toxicity, especially platelet toxicity, correlated significantly with the administered activity (r = 0.85), whole-body absorbed dose (r = 0.65), and red marrow dose (r = 0.62 and 0.75). An inverse relationship between the mass and absorbed dose of the tumor lesions was observed. Calculated mean absorbed doses were similar for the simulated and measured (177)Lu-cG250 data. Absorbed doses (whole body and red marrow) based on the simulated (177)Lu-cG250 data correlated with the observed platelet toxicity (r = 0.65 and 0.82). The tumor-to-red marrow dose ratio was higher for radioimmunotherapy with (177)Lu-cG250 than for radioimmunotherapy with (90)Y-cG250, indicating that (177)Lu has a wider therapeutic window for radioimmunotherapy with cG250 than (90)Y., Conclusion: In patients with metastasized renal cell carcinoma, hematologic toxicity after treatment with (177)Lu-cG250 can be predicted on the basis of administered activity and whole-body and red marrow-absorbed dose. Diagnostic (111)In-cG250 data can be used to accurately predict absorbed doses and myelotoxicity of radioimmunotherapy with (177)Lu-cG250. These estimations indicate that in these patients, higher radiation doses can be guided to the tumors with (177)Lu-cG250 than with (90)Y-cG250.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results